20. Defendant Barr Pharmaceuticals LLC f/k/a Barr Pharmaceuticals, Inc. is aDelaware corporation with its principal place of business in New Jersey.Defendant BarrPharmaceuticals, Inc. was acquired by Defendant Teva Pharmaceuticals USA, Inc. on December23, 2008 and is therefore a wholly owned subsidiary of Defendant Teva Pharmaceuticals USA,Inc. Defendant Barr Pharmaceuticals, Inc. was involved in the research, testing, manufacture,distribution, marketing, promotion sale, labeling, and design of metoclopramide detailed below.Defendant regularly conducts business in Philadelphia County, Pennsylvania. Pursuant to CaseManagement Order No. 1, Defendant may be served with process by registered mail, returnreceipt requested, upon: Ms. Jennifer Fuller-Ricciardi, Teva Pharmaceuticals USA, Inc., 425Privet Road, P.O. Box 1005, Horsham, PA 19044.21. Defendant Barr Laboratories, Inc. is a Delaware corporation with its principalplace of business in New York. Defendant Barr Laboratories, Inc was acquired by DefendantTeva Pharmaceuticals USA, Inc. on December 23, 2008 and is therefore a wholly ownedsubsidiary of Defendant Teva Pharmaceuticals USA, Inc. Defendant Barr Laboratories, Inc wasinvolved in the research, testing, manufacture, distribution, marketing, promotion, sale, labeling,and design of metoclopramide detailed below. Defendant regularly conducts business inPhiladelphia County, Pennsylvania. Pursuant to Case Management Order No. 1, Defendant maybe served with process by registered mail, return receipt requested, upon: Ms. Jennifer Fuller-Ricciardi, Teva Pharmaceuticals USA, Inc., 425 Privet Road, P.O. Box 1005, Horsham, PA19044.22. Defendant Duramed Pharmaceuticals, Inc. is a Delaware corporation with itsprincipal place of business in Ohio. Defendant Barr Pharmaceuticals, Inc. is the parent companyfor Defendant Duramed Pharmaceuticals, Inc. and was acquired by Defendant Teva- 18 -Case ID: 100101997
Pharmaceuticals USA, Inc. on December 23, 2008. Defendant Duramed Pharmaceuticals, Inc.was involved in the research, testing, manufacture, distribution, marketing, promotion, sale,labeling, and design of metoclopramide detailed below. Defendant regularly conducts businessin Philadelphia County, Pennsylvania. Defendant may be served with process by registered mail,return receipt requested, upon: Ms. Jennifer Fuller-Ricciardi, Teva Pharmaceuticals USA, Inc.,425 Privet Road, P.O. Box 1005, Horsham, PA 19044.23. Defendant Qualitest Pharmaceuticals, Inc., Individually and d/b/a VintagePharmaceuticals, Inc., is an Alabama corporation with a principal place of business in Alabama.Defendant regularly conducts business in Philadelphia County, Pennsylvania. Defendant wasinvolved in the research, testing, manufacture, distribution, marketing, promotion, sale, labeling,and design of metoclopramide detailed below. Pursuant to Case Management Order No. 1,Defendant may be served with process by registered mail, return receipt requested, upon: JamesM. Campbell, Esquire, Campbell, Campbell, Edwards & Conroy, P.C., One Constitution Plaza,Boston, Massachusetts 02129 and Kristen E. Dennison, Esquire, Campbell, Campbell, Edwards& Conroy, P.C., 690 Lee Road, Suite 300, Wayne, PA 19087.24. Defendant Generics Bidco I., LLC, Individually and d/b/a QualitestPharmaceuticals is a Delaware corporation with a principal place of business in Alabama.Defendant regularly conducts business in Philadelphia County, Pennsylvania. Defendant wasinvolved in the research, testing, manufacture, distribution, marketing, promotion, sale, labelingand design of metoclopramide detailed below. Pursuant to Case Management Order No.1,Defendant may be served with process by registered mail, return receipt requested, upon: JamesM. Campbell, Esquire, Campbell, Campbell, Edwards & Conroy, P.C., One Constitution Plaza,- 19 -Case ID: 100101997
- Page 1 and 2: IN RE ::COURT OF COMMON PLEASPHILAD
- Page 4: Sears Tower - Suite 5500Chicago, IL
- Page 7 and 8: 4 Penn Center, Suite 8001600 John F
- Page 9 and 10: Northstar Rx LLC4971 Southridge Blv
- Page 11 and 12: Richmond Pharmaceuticals, Inc.3510
- Page 13 and 14: Jersey 07940. Defendant regularly c
- Page 15 and 16: 12. Defendant Baxter Healthcare Cor
- Page 17: with process via The Hague Conventi
- Page 21 and 22: Case Management Order No. 1, Defend
- Page 23 and 24: 34. Defendant Watson Laboratories,
- Page 25 and 26: through its registered agent for se
- Page 27 and 28: 47. Defendant VistaPharm, Inc. is a
- Page 29 and 30: labeling, and design of metoclopram
- Page 31 and 32: metoclopramide not yet known by Pla
- Page 33 and 34: packaging and/or advertising the ph
- Page 35 and 36: 76. In addition, Philadelphia Count
- Page 37 and 38: 87. The ―indications‖ (recommen
- Page 39 and 40: e satisfied that the proposed label
- Page 41 and 42: prescribed by physicians, most of w
- Page 43 and 44: exercise of reasonable care should
- Page 45 and 46: 113. Since 1985, GENERIC DEFENDANTS
- Page 47 and 48: e. independently monitor the sales
- Page 49 and 50: disfigurement, disability, pain and
- Page 51 and 52: care industry and consumers, includ
- Page 53 and 54: associated with the ordinary, expec
- Page 55 and 56: 146. The Reglan and/or generic meto
- Page 57 and 58: 158. Each of the DRUG COMPANY DEFEN
- Page 59 and 60: 22. They failed to implement proper
- Page 61 and 62: 166. As lawful consumers of Reglan
- Page 63 and 64: duration of use - confirming they w
- Page 65 and 66: involuntary movements, aggravation
- Page 67 and 68: DEFENDANTS professed to Plaintiffs
- Page 69 and 70:
COUNT VIII - UNFAIR AND DECEPTIVE T
- Page 71 and 72:
loss: the difference between the pr
- Page 73 and 74:
214. BRAND NAME DEFENDANTS knew, or
- Page 75 and 76:
217. Alternatively or in addition,
- Page 77 and 78:
224. In addition, DRUG COMPANY DEFE
- Page 79 and 80:
237. The representatives of Deceden
- Page 81 and 82:
248. Plaintiffs also allege that th
- Page 83 and 84:
d) They continued to promote the sa
- Page 85:
(G)Such other relief as is deemed j